Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (921-930 of 934) with videos related to

Pageof 94
Sort By:
JAMA|March 17, 2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trialMatthew J Price, Peter B Berger, Paul S Teirstein, et al.
The New England Journal of Medicine|November 17, 2020
Sotagliflozin in Patients with Diabetes and Chronic Kidney DiseaseDeepak L Bhatt, Michael Szarek, Bertram Pitt, et al.
The New England Journal of Medicine|April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Meg J Jardine, Bruce Neal, et al.
Circulation|July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention GroupsKenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.
The Lancet. Diabetes & Endocrinology|February 17, 2025
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trialRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
JAMA|November 4, 2004
Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement InitiativeDeepak L Bhatt, Matthew T Roe, Eric D Peterson, et al.
JAMA|September 1, 2014
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trialMichelle L O'Donoghue, Eugene Braunwald, Harvey D White, et al.
Circulation|February 8, 2021
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE TrialNan Ye, Meg J Jardine, Megumi Oshima, et al.
Journal of the American College of Cardiology|August 27, 2025
A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular RiskPaul M Haller, Giorgio E M Melloni, David D Berg, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|February 16, 2007
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases, C Ballantyne, M Cushman, et al.
Pageof 94

Showing results (921-930 of 934) with videos related to

Sort By:
Pageof 94
JAMA|March 17, 2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trialMatthew J Price, Peter B Berger, Paul S Teirstein, et al.
The New England Journal of Medicine|November 17, 2020
Sotagliflozin in Patients with Diabetes and Chronic Kidney DiseaseDeepak L Bhatt, Michael Szarek, Bertram Pitt, et al.
The New England Journal of Medicine|April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Meg J Jardine, Bruce Neal, et al.
Circulation|July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention GroupsKenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.
The Lancet. Diabetes & Endocrinology|February 17, 2025
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trialRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
JAMA|November 4, 2004
Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement InitiativeDeepak L Bhatt, Matthew T Roe, Eric D Peterson, et al.
JAMA|September 1, 2014
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trialMichelle L O'Donoghue, Eugene Braunwald, Harvey D White, et al.
Circulation|February 8, 2021
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE TrialNan Ye, Meg J Jardine, Megumi Oshima, et al.
Journal of the American College of Cardiology|August 27, 2025
A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular RiskPaul M Haller, Giorgio E M Melloni, David D Berg, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|February 16, 2007
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases, C Ballantyne, M Cushman, et al.
Pageof 94